Summit Therapeutics plc and Chinese partner Akeso Inc.'s quest to develop a potential global challenger to Merck & Co., Inc.’s blockbuster Keytruda (pembrolizumab) in the advanced or metastatic non-small cell lung cancer (NSCLC) space is poised to expand to the US firm’s most formidable stronghold – as a monotherapy for the first-line treatment of tumors with PD-L1-high expression (PD-L1 TPS (tumor promotion score) >50%).
Key Takeaways
-
The anti-PD-1/VEGF bispecific antibody ivonescimab bested Keytruda as monotherapy in the first-line setting in terms of progression-free survival in NSCLC in the head-to-head Phase III HARMONi-2 trial.
-
The study enrolled Chinese patients with PD-L1-expressing tumors, a broader group than that eligible for current standard-of-care Keytruda monotherapy in the US
Last week, Summit/Akeso claimed that in the head-to-head Phase III HARMONi-2 trial, their anti-PD-1/VEGF bispecific antibody ivonescimab bested Keytruda as monotherapy in the first-line setting in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?